Orthofix exec sells 150 shares at $9.39

An Orthofix Medical executive sold 150 OFIX shares under a pre-set Rule 10b5-1 trading plan and continues to hold over fifty thousand shares, including restricted stock units.

Rhea-AI Filing Summary

Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, its President, Global Limb Recon, sold 150 shares of common stock on September 1, 2026 at $9.39 per share in an open-market transaction under a Rule 10b5-1 trading plan. After this sale, he directly holds 51,069 shares, which include 36,028 previously reported restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 150 shares

Net Sell 1 txn

Insider Fisher Patrick

Role President, Global Limb Recon

Sold 150 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	150	$9.39	$1K

Holdings After Transaction: Common Stock — 51,069 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.
2. F2. Includes 36,028 previously reported restricted stock units.

Key Figures

Shares sold: 150 shares Sale price per share: $9.39 per share Shares held after transaction: 51,069 shares +2 more

5 metrics

Shares sold 150 shares Common stock sale on September 1, 2026 by Patrick Fisher

Sale price per share $9.39 per share Price for the 150 OFIX shares sold on September 1, 2026

Shares held after transaction 51,069 shares Direct ownership by Patrick Fisher following the September 1, 2026 sale

Restricted stock units included 36,028 restricted stock units Included within the 51,069 shares held after the sale

Rule 10b5-1 plan adoption date May 29, 2026 Date Patrick Fisher adopted the Rule 10b5-1 trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, restricted stock units, common stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 36,028 previously reported restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

common stock financial

"150 shares of common stock on September 1, 2026 at $9.39 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Orthofix Medical (OFIX) disclose in this Form 4?

Orthofix Medical disclosed that Patrick Fisher, President, Global Limb Recon, sold 150 shares of common stock on September 1, 2026 at a price of $9.39 per share in an open-market or private transaction.

How many OFIX shares did the Orthofix Medical executive sell and at what price?

Patrick Fisher sold 150 shares of Orthofix Medical common stock at $9.39 per share on September 1, 2026, as reported in the Form 4 filing.

How many Orthofix Medical (OFIX) shares does Patrick Fisher own after this sale?

After the reported sale, Patrick Fisher directly owns 51,069 shares of Orthofix Medical common stock. This total includes 36,028 previously reported restricted stock units as noted in the filing footnote.

Was the OFIX insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Patrick Fisher on May 29, 2026, indicating the trade was pre-arranged under that plan.

What is Patrick Fisher’s role at Orthofix Medical (OFIX)?

Patrick Fisher is identified in the filing as an officer of Orthofix Medical, serving as President, Global Limb Recon, and he is the reporting person for this Form 4 transaction.

Do Patrick Fisher’s holdings include restricted stock units of OFIX?

Yes. A footnote explains that his post-transaction total of 51,069 shares includes 36,028 previously reported restricted stock units, which are part of his direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:52 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher Patrick

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TEXAS 75056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Global Limb Recon

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		150	D	$9.39	51,069(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.

2. Includes 36,028 previously reported restricted stock units.

	/s/ J. Andres Cedron, Attorney-in-fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)